Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.2104-2105
Hauptverfasser: Paiva, Bruno, Manrique, Irene, Rytlewski, Julie A, Campbell, Timothy B., Kazanecki, Christian, Martin, Nathan, Kaiser, Shari M., Anderson, Larry D., Berdeja, Jesus, Lonial, Sagar, Raje, Noopur, Lin, Yi, Moreau, Philippe, San-Miguel, Jesús, Munshi, Nikhil C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2105
container_issue Supplement 1
container_start_page 2104
container_title Blood
container_volume 140
creator Paiva, Bruno
Manrique, Irene
Rytlewski, Julie A
Campbell, Timothy B.
Kazanecki, Christian
Martin, Nathan
Kaiser, Shari M.
Anderson, Larry D.
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Lin, Yi
Moreau, Philippe
San-Miguel, Jesús
Munshi, Nikhil C
description
doi_str_mv 10.1182/blood-2022-166658
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122024144</els_id><sourcerecordid>S0006497122024144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1858-d4ef3073f28e056f2c2b3ecafb21318092c74d808ff3778845e6ee8865d9c5643</originalsourceid><addsrcrecordid>eNp9UblOAzEQtRBIhOMD6KYkxYLtvRxRIRIOQQTialdeexyMnF1keyPl-_gxHEJNNU8jvWPmEXLC6Bljgp-3ru91xinnGauqqhQ7ZMRKLjJKOd0lI0pplRWTmu2TgxA-KWVFzssR-Z5J79YgOw0vQ4jSdqjhrdMYUUXZOoQ5yjD4X_iMwepBOpjakLYIp_Pn6RikiejhTqOSbZQL7BDerXI4KHRwajVmCYxhiiapB5DJqQ0YoTcwH1y0XxuXNbp-KZPifAxPMlrsYgDbwb30y7S_VB8WV7ZbwJPvXd8tcBPYr-xKuiOyZ6QLePw3D8nb9ez16jZ7eLy5u7p8yBQTpch0gSandW64QFpWhive5imzaTnLmaATrupCCyqMyetaiKLEClGIqtQTVVZFfkjYVlf5PgSPpvnydin9umG02bTQ_LbQbFpoti0kzsWWgynYyqJvgkq3KdTWpw83urf_sH8AytKR2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie A ; Campbell, Timothy B. ; Kazanecki, Christian ; Martin, Nathan ; Kaiser, Shari M. ; Anderson, Larry D. ; Berdeja, Jesus ; Lonial, Sagar ; Raje, Noopur ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús ; Munshi, Nikhil C</creator><creatorcontrib>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie A ; Campbell, Timothy B. ; Kazanecki, Christian ; Martin, Nathan ; Kaiser, Shari M. ; Anderson, Larry D. ; Berdeja, Jesus ; Lonial, Sagar ; Raje, Noopur ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús ; Munshi, Nikhil C</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166658</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.2104-2105</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1858-d4ef3073f28e056f2c2b3ecafb21318092c74d808ff3778845e6ee8865d9c5643</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Manrique, Irene</creatorcontrib><creatorcontrib>Rytlewski, Julie A</creatorcontrib><creatorcontrib>Campbell, Timothy B.</creatorcontrib><creatorcontrib>Kazanecki, Christian</creatorcontrib><creatorcontrib>Martin, Nathan</creatorcontrib><creatorcontrib>Kaiser, Shari M.</creatorcontrib><creatorcontrib>Anderson, Larry D.</creatorcontrib><creatorcontrib>Berdeja, Jesus</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Raje, Noopur</creatorcontrib><creatorcontrib>Lin, Yi</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>San-Miguel, Jesús</creatorcontrib><creatorcontrib>Munshi, Nikhil C</creatorcontrib><title>Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UblOAzEQtRBIhOMD6KYkxYLtvRxRIRIOQQTialdeexyMnF1keyPl-_gxHEJNNU8jvWPmEXLC6Bljgp-3ru91xinnGauqqhQ7ZMRKLjJKOd0lI0pplRWTmu2TgxA-KWVFzssR-Z5J79YgOw0vQ4jSdqjhrdMYUUXZOoQ5yjD4X_iMwepBOpjakLYIp_Pn6RikiejhTqOSbZQL7BDerXI4KHRwajVmCYxhiiapB5DJqQ0YoTcwH1y0XxuXNbp-KZPifAxPMlrsYgDbwb30y7S_VB8WV7ZbwJPvXd8tcBPYr-xKuiOyZ6QLePw3D8nb9ez16jZ7eLy5u7p8yBQTpch0gSandW64QFpWhive5imzaTnLmaATrupCCyqMyetaiKLEClGIqtQTVVZFfkjYVlf5PgSPpvnydin9umG02bTQ_LbQbFpoti0kzsWWgynYyqJvgkq3KdTWpw83urf_sH8AytKR2g</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Paiva, Bruno</creator><creator>Manrique, Irene</creator><creator>Rytlewski, Julie A</creator><creator>Campbell, Timothy B.</creator><creator>Kazanecki, Christian</creator><creator>Martin, Nathan</creator><creator>Kaiser, Shari M.</creator><creator>Anderson, Larry D.</creator><creator>Berdeja, Jesus</creator><creator>Lonial, Sagar</creator><creator>Raje, Noopur</creator><creator>Lin, Yi</creator><creator>Moreau, Philippe</creator><creator>San-Miguel, Jesús</creator><creator>Munshi, Nikhil C</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival</title><author>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie A ; Campbell, Timothy B. ; Kazanecki, Christian ; Martin, Nathan ; Kaiser, Shari M. ; Anderson, Larry D. ; Berdeja, Jesus ; Lonial, Sagar ; Raje, Noopur ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús ; Munshi, Nikhil C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1858-d4ef3073f28e056f2c2b3ecafb21318092c74d808ff3778845e6ee8865d9c5643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Manrique, Irene</creatorcontrib><creatorcontrib>Rytlewski, Julie A</creatorcontrib><creatorcontrib>Campbell, Timothy B.</creatorcontrib><creatorcontrib>Kazanecki, Christian</creatorcontrib><creatorcontrib>Martin, Nathan</creatorcontrib><creatorcontrib>Kaiser, Shari M.</creatorcontrib><creatorcontrib>Anderson, Larry D.</creatorcontrib><creatorcontrib>Berdeja, Jesus</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Raje, Noopur</creatorcontrib><creatorcontrib>Lin, Yi</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>San-Miguel, Jesús</creatorcontrib><creatorcontrib>Munshi, Nikhil C</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paiva, Bruno</au><au>Manrique, Irene</au><au>Rytlewski, Julie A</au><au>Campbell, Timothy B.</au><au>Kazanecki, Christian</au><au>Martin, Nathan</au><au>Kaiser, Shari M.</au><au>Anderson, Larry D.</au><au>Berdeja, Jesus</au><au>Lonial, Sagar</au><au>Raje, Noopur</au><au>Lin, Yi</au><au>Moreau, Philippe</au><au>San-Miguel, Jesús</au><au>Munshi, Nikhil C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>2104</spage><epage>2105</epage><pages>2104-2105</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166658</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.2104-2105
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_166658
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A20%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20and%20Sustained%20Undetectable%20Measurable%20Residual%20Disease%20(MRD)%20after%20Idecabtagene%20Vicleucel%20(ide-cel)%20Defines%20a%20Subset%20of%20Multiple%20Myeloma%20(MM)%20Patients%20in%20Karmma%20Achieving%20Prolonged%20Survival&rft.jtitle=Blood&rft.au=Paiva,%20Bruno&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=2104&rft.epage=2105&rft.pages=2104-2105&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166658&rft_dat=%3Celsevier_cross%3ES0006497122024144%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122024144&rfr_iscdi=true